Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study

BACKGROUND The purpose of this study was to assess the efficacy and safety and to explore the dose response of esketamine intravenous (IV) infusion in patients with treatment-resistant depression (TRD). METHODS This multicenter, randomized, placebo-controlled trial was conducted in 30 patients with TRD. Patients were randomly assigned 1:1:1 to receive an IV infusion of .20 mg/kg or .40 mg/kg esketamine or placebo over 40 minutes on day 1. The primary end point was change in Montgomery-Åsberg Depression Rating Scale total score from day 1 (baseline) to day 2. Nonresponders who received placebo on day 1 were randomly assigned again 1:1 to IV esketamine .20 mg/kg or .40 mg/kg on day 4. Secondary efficacy and safety measures were also evaluated. RESULTS Of the enrolled patients, 97% (29 of 30) completed the study. The least squares mean changes (SE) from baseline to day 2 in Montgomery-Åsberg Depression Rating Scale total score for the esketamine .20 mg/kg and .40 mg/kg dose groups were -16.8 (3.00) and -16.9 (2.61), respectively, and showed significant improvement (one-sided p = .001 for both groups) compared with placebo (-3.8 [2.97]). Esketamine showed a rapid (within 2 hours) and robust antidepressant effect. Treatment-emergent adverse events were dose dependent. The most common treatment-emergent adverse events were headache, nausea, and dissociation; the last-mentioned was transient and did not persist beyond 4 hours from the start of the esketamine infusion. CONCLUSIONS A rapid onset of robust antidepressant effects was observed in patients with TRD after a 40-minute IV infusion of either .20 mg/kg or .40 mg/kg of esketamine. The lower dose may allow for better tolerability while maintaining efficacy.

[1]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.

[2]  D. Charney,et al.  Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression , 2010, Biological Psychiatry.

[3]  E. Linardatos,et al.  Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes , 2013, PLoS medicine.

[4]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[5]  John H Krystal,et al.  Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.

[6]  D. Charney,et al.  Is There Anything Really Novel on the Antidepressant Horizon? , 2012, Current Psychiatry Reports.

[7]  M. Durieux,et al.  Ketamine: Teaching an Old Drug New Tricks , 1998, Anesthesia and analgesia.

[8]  D. Luckenbaugh,et al.  Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. , 2010, The Journal of clinical psychiatry.

[9]  M. Fava,et al.  Definition and epidemiology of treatment-resistant depression. , 1996, The Psychiatric clinics of North America.

[10]  Bradley N Gaynes,et al.  What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. , 2009, Psychiatric services.

[11]  M. Case,et al.  A randomized, double‐blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment‐resistant depression , 2006, Depression and anxiety.

[12]  K. Lapidus,et al.  Novel glutamatergic drugs for the treatment of mood disorders , 2013, Neuropsychiatric disease and treatment.

[13]  Dennis S. Charney,et al.  Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression , 2013, Biological Psychiatry.

[14]  K. L. Leenders,et al.  Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET) , 1997, European Neuropsychopharmacology.

[15]  D. Kupfer,et al.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. , 2006, The American journal of psychiatry.

[16]  H. Scheinin,et al.  Pharmacokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity , 2002, European Journal of Clinical Pharmacology.

[17]  D. Luckenbaugh,et al.  Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study , 2012, Neuropsychopharmacology.

[18]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[19]  D. Charney,et al.  A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder , 2014, Biological Psychiatry.

[20]  G. Geisslinger,et al.  Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. , 1993, British journal of anaesthesia.

[21]  Leslie Muetzelfeldt,et al.  Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. , 2010, Addiction.

[22]  M. Poo,et al.  Grand challenges in global mental health , 2011, Nature.

[23]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[24]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[25]  S. Rauch,et al.  Neurobiology of emotion perception II: implications for major psychiatric disorders , 2003, Biological Psychiatry.

[26]  J. Murrough.  Ketamine as a Novel Antidepressant: From Synapse to Behavior , 2012, Clinical pharmacology and therapeutics.

[27]  M H Trivedi,et al.  The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation , 2004, Psychological Medicine.

[28]  O. Paulsen,et al.  Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors. , 1992, The Journal of pharmacology and experimental therapeutics.

[29]  C. Clark,et al.  Ketamine for Treatment-Resistant Unipolar Depression: Current Evidence , 2016 .

[30]  D. Charney,et al.  Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. , 2010, The international journal of neuropsychopharmacology.

[31]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[32]  Dan V Iosifescu,et al.  Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. , 2013, The American journal of psychiatry.

[33]  G. Dunbar,et al.  The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability , 1997, European Psychiatry.

[34]  T. Hergueta,et al.  The mini international neuropsychiatric interview , 1998, European Psychiatry.

[35]  J. Krystal,et al.  Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. , 2004, The American journal of psychiatry.